20150318 smb hve quirem medical jan sigger
11
March 2015 QuiremSpheres® The Next Generation Microspheres for Radioembolisation “Treat what you see and see what you treat”
Transcript of 20150318 smb hve quirem medical jan sigger
March 2015
QuiremSpheres® The Next Generation Microspheres for Radioembolisation
“Treat what you see and see what you treat”
Agenda
• Company Profile
• Management Team
• Cancer in the liver
• The radioembolisation market
• QuiremSpheres®
• Company timeline
• Main start-up challenges
2
• Spin-off in 2013 from the University Medical Center
Utrecht
• 20 years of development on Holmium microspheres
• Superior proposition in fast growing radioembolisation
market for liver malignancies
• Higher dose rate ensures more effective tumor kill
• Unique imaging capabilities enable personalized, real-time,
image-guided treatment
• Supported by state-of-the-art administration device and
industry first SW treatment planning & evaluation solution
• Preparing for product launch early 2015
• Strong IP position
• Management team with proven track record
Company ProfileSuperior proposition in fast growing market
Jan Sigger – Chief Executive Officer
Held senior management positions at Royal Dutch Shell and Akzo Nobel.
Joint Nucletron, the global market leader in brachytherapy, as CFO in 2008.
Transformed Nucletron into the fastest growing radiotherapy company and
managed the sale from private equity ownership to Elekta AB in 2011. Jan Sigger
Chief Executive Officer
M: +31 6 20545977
Management TeamQuirem Medical has a seasoned team with relevant experience
Frank Nijsen – Chief Scientific Officer
Performed 20 years of research into Holmium microspheres.
Led the successful valorisation of the Holmium technology and was
instrumental in the creation of the spin-off company Quirem Medical.
Holds as inventor many patents in the radioembolization field. Frank Nijsen
Chief Scientific Officer
M: +31 6 40675781
5* Globocan 2012 data
High medical needLife expectancy is low for both primary and metastasized liver cancer
Liver:
• 70% portal vein
• 30% hepatic artery
Tumor:
• 99% hepatic artery
Radioembolisation of the liverMaximising the dose to the tumor
MRI of distribution of
paramagnetic QuiremSpheres - energy 1.84 MeV
166Ho- energy 81 keV
165Honeutron
QuiremSpheres®
Neutron activation and characteristics
See what you treat and treat what you see
Before treatment After treatment
19 Gy135 Gy
35 Gy
19 Gy135 Gy
35 Gy
Anatomical MRI Nuclear imaging QuiremSpheres™ sensitive MRI
Tumor 1Tumor 2
• Personalized local treatment• Optimal radiation dose to the tumor• Minimal side effects• Treatment planning & evaluation
(no more black box)• Follow-up treatment if needed
Imaging capabilities QuiremSpheres®
Enabling treatment planning & evaluation and real-time image guided treatment
9
Clinical evidence is growingSuccessful phase 1 study, phase 2 study almost completed, 3rd and 4th study started,
5th study for intratumoral head & neck treatment recently approved
Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study
Maarten Smits, Johannes Nijsen, Maurice van den Bosch, Marnix Lam, Maarten Vente, Willem Mali, Alfred van het Schip, Bernard Zonnenberg
Lancet Oncology 2012 Oct;13(10):1025-34.
Main start-up challengesMake sure to timely address the key factors for success by creating:
• The right team (priority 1,2 and 3)
• The right information
• Business plan
• Financial plan
• IP landscape
• The right support
• Legal
• Financial
• Regulatory
• The right partners
• Technical
• Commercial
• The right investors
• Funding capabilities
• Time horizon
• Network
10
…a personalized way to fight liver cancer
QuiremSpheres®
